Diana Ernst, RPh

A significant percentage of affected patients were observed to have dilated atria and left ventricular hypertrophy.

Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.

Telmisartan, an angiotensin II receptor blocker, is indicated for the treatment of hypertension.

Twice-yearly dosing with inclisiran sodium resulted in significant lowering of low-density lipoprotein cholesterol.

Treatment with sacubitril/valsartan provides greater benefits in certain patients with HFpEF, according to analyses from the phase 3 PARAGON-HF trial.

Treatment with empagliflozin, a SGLT2 inhibitor, was associated with reduced risk of hospitalization for heart failure.

This retrospective, single-center study included 143 patients who were newly initiated on sacubitril/valsartan during their hospitalization.

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening heart failure when added to standard of care treatment in patients with reduced ejection fraction.